About this episode
The MYC oncogene is notorious in the cancer research world because it is implicated in many advanced or aggressive cancers such as treatment-resistant prostate cancer. In this episode, Sarki Abdulkadir, MD, PhD, shares how his team bucked the conventional notion that the MYC gene is "undruggable" and uncovered a handful of compounds that block MYC gene activity, making prostate cancer tumors sensitive to hormone therapy and opening up a potential new therapeutic target for treatment-resistant prostate cancer.
